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Abbreviations 
AA, arachidonic acid 
ACO2, aconitate hydratase 
ACTB, beta-actin 
ALE, advanced lipoxidation endproduct 
ATP5F1A, ATP synthase subunit alpha 
ATP5F1B, ATP synthase subunit beta 
BASP1, brain acid soluble protein 1 
BLVRB, NADPH-flavin reductase 
CA1, carbonic anhydrase 1 
CEL, carboxyethyl-lysine 
ChoGpl, glycerophosphocholines 
CKB, creatine kinase B-type 
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CMRg, cerebral metabolic rate of glucose 
COX, cyclooxigenases 
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CRYAB, alpha-crystallin B chain (heat shock protein B5) 
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DLD, dihydrolipoyl dehydrogenase 
DPYSL2, dihydropyrimidinase-related protein 2 
ENO1, alpha-enolase 
ENO2, gamma-enolase 
EtbGpl, glycerophosphoethanolamines 
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GFAP, glial fibrillary acidic protein 
GL, glycerolipids 
GLUD1, glutamate dehydrogenase 1 
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GOT1, aspartate aminotransferase 
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GST, glutathione-S-transferase 
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HSPD1, heat shock protein 60KDa 
IF, intermittent fasting 
IMS, imaging mass spectrometry 
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LOX, lipoxigenases 
MDA, malondialdehyde 
MetR, methionine restriction 
MRI, magnetic resonance image 
MS, mass spectrometry 
MUFA, monounsaturated fatty acids 
NEFL, neurofilament light polypeptide 
NEFM, neurofilament medium polypeptide 
NKT, neuroketals 
Nrf2, nuclear factor erythroid 2-related factor 
ONE, 4-oxo-2-nonenal 
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PFC, prefrontal cortex 
PGAM1, phosphoglycerate mutase 1 
PI, peroxidizability index 
PIGpl, phosphatidylinositols 
PKM, pyruvate kinase 
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UCP, uncoupling protein 
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Abstract 
Human prefrontal cortex (PFC) is a recently evolutionary emerged brain region involved in 
cognitive functions. Human cognitive abilities decline during aging. Yet the molecular 
mechanisms that sustain the preservation or deterioration of neurons and PFC functions 
are unknown. In this review, we focus on the role of lipids in human PFC aging. As the 
evolution of brain lipid concentrations is particularly accelerated in the human PFC, 
conferring a specific lipid profile, a brief approach to the lipidome of PFC was consider 
along with the relationship between lipids and lipoxidative damage, and the role of lipids 
in human PFC aging. In addition, the specific targets of lipoxidative damage in human PFC, 
the affected biological processes, and their potential role in the cognitive decline 
associated with aging are discussed. Finally, interventions designed to modify this process 
are considered.  We propose that the dysfunction of key biological processes due to 
selective protein lipoxidation damage may have a role the cognitive decline of PFC during 
aging.  
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1. Introduction 
One critical trait of human evolution is the rapid expansion of brain size and the 
emergence of unique and complex cognitive capabilities. These changes have demanded 
metabolic adaptations, in particular with respect to increased energy supplies [1]. Thus, 
humans allocate about 20% of their total energy to the brain, compared with 12% for 
apes and 5% for other mammalian species [2]. This higher metabolic activity, supported 
by increased expression of genes related to neuronal functions and energy metabolism [3, 
4], as well as the increased density of glia cells relative to neurons [5, 6], shows its 
greatest demand in human prefrontal cortex (PFC) [5, 7]. Furthermore, PFC has been 
shown to undergo greater expansion at the gross anatomy level in human evolutionary 
lineage than other brain regions [8]; it is the brain region that has emerged and evolved 
most recently during primate evolution. PFC is involved in complex cognitive functions 
including reasoning, planning, social behavior, and general intelligence [9-11]. 
Cognitive abilities decline during aging. Yet brain aging does not affect all neurons 
identically. Non-invasive techniques such as structural brain imaging and functional 
magnetic resonance imaging (MRI) are being widely used and combined with post-
mortem analyses of aging human brain to identify the most age-sensitive regions of the 
brain. Volumetric brain measurements as well as positron emission tomography (PET) 
measures of whole brain and regional cerebral metabolic rates of glucose (CMRg) 
reinforce the idea that aging affects some brain regions more than others. Thus, in 
addition to the volume changes in, particularly, the association cortex during aging, it has 
been shown that the PFC shows the greatest and most consistent decrements in CMRg as 
compared with all other regions of the aging brain [12-15]. In this line, cognitive functions 
that rely on PFC, such as learning, memory, and executive functions, show considerable 
age-related decline. Consequently, it is plausible to postulate that the decline in both 
energy metabolism and cognition are closely linked. 
These changes in metabolic activity in PFC during aging have been associated with 
different, and non-exclusive, molecular mechanisms and biological processes comprising 
altered neuronal expression of proteins involved in the metabolic state of neurons and 
glial cells, altered activation of synapses, and the disruptive effects of abnormal neuronal 
excitability. But, in any case, the evidence clearly suggests that neuronal loss during aging 
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is very modest, whereas a decrease in the number of synapses appears to be a more 
prominent trait of brain aging. Indeed, most of the functional decline associated with 
physiological aging is caused by relatively subtle changes, such as loss of dendrites, 
reductions in spine density, altered spine morphology, changes in the molecular profile of 
synapses, and a general loss of synaptic plasticity, all of which is paralleled by declining 
cognitive function and elevated risk of neurodegenerative disease [16-22]. Nevertheless, 
the molecular mechanisms behind aging-related phenotypic changes are only scarcely 
understood. 
Lipids have allowed and lent support to the brain’s evolution toward complexity [23]. In 
addition to their quantitative relevance (50% of the dry matter [24]), brain lipids show 
great structural and functional diversity, with most lipid categories represented in cells as 
expressions of the different needs and functions ascribed to them which are related to 
the generation of membranes, cell signaling, and energy storage [23,25]. By regulating the 
chemical and physical properties of membranes, lipids direct vesicle fusion and fission 
processes, ion flux, and lateral diffusion of membrane proteins, they also create the 
microdomains necessary for optimal cellular communication, among other functions [26] 
[27, 28]. However, despite growing evidence of the critical role of lipids in brain function, 
little is known about the participation of lipids in PFC aging. In this review, we used data 
from targeted and untargeted mass spectrometry (MS)-based lipidomics and redox 
lipidomics to characterize the lipidome composition of human PFC and its association 
with the cognitive decline linked to the aging process.  
 
2. Lipidomics of human prefrontal cortex 
Recent progress in mass spectrometry (MS)-based lipidomics has provided experimental 
opportunities for the large-scale quantitative profiling of thousands of individual lipid 
molecular species in human brain, providing novel insights into the mechanisms and 
evolution of brain functionality. Thus, current data demonstrate the existence of 
lipidomic signatures which are tissue-specific [29, 30] and brain region-dependent [29, 31, 
32], with the lipid profile of the brain seen to be markedly different from that of the other 
tissues (verified in mammals, non-human primates, and humans) [29]. This supports the 
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idea that lipids play specific roles in brain function [25]. Interestingly, the largest lipidome 
divergence between the brain and other tissues is found in humans, who show the 
greatest cognitive complexity. Furthermore, lipidome divergence follows the genetic 
divergence among animal species, supporting the idea that concentration levels of lipids 
enriched in brain evolved at a much more rapid pace than the concentration levels of 
lipids characteristic of non-neural tissues [29]. As stated by Khaitovich and coworkers 
[29], these features suggest a link between brain lipidome evolution and the evolution of 
brain functionality. 
Importantly, the greater acceleration of lipidome changes in the human evolutionary 
lineage is specific to brain enriched lipids in PFC, the region commonly associated with 
human-specific brain functions. Lipids showing human PFC-specific concentration changes 
belong to three lipid categories: glycerolipids (GL), glycerophospholipids (GP), and 
sphingolipids (SP); these in turn are represented in very specific lipid subclasses, namely: 
1-(1Z-alkenyl), 2-acylglycerophosphoethanolamines (plasmalogens of 
phosphatidylethanolamines), diacylglycerols, N-acylsphinganines (dihydroceramides), and 
N-acylsphingosines (ceramides) [29]. 
This specific lipid pattern present in human PFC seems to also be projected and reflected 
at the cellular, subcellular, and molecular levels. Thus, for example, at the cellular level, 
by using imaging mass spectrometry (IMS) [33, 34] it is possible to generate density maps 
for several lipid species, mainly glycerophosphocholines (ChoGpl), 
glycerophosphoethanolamines (EtnGpl), and sphingomyelins (SM), offering important 
information about the lipidome of the human brain and, in particular, the human PFC. 
The IMS images show that the diverse lipid molecular species found in human PFC exhibit 
a different and specific distribution, and even allow us to distinguish among the six 
different layers of the PFC based on the slight differences in lipid density throughout the 
cortex [33] (see Figure 1). 
A recent study has used a lipidomic approach to analyze the lipid profile at the 
mitochondrial and microsomal levels in grey matter of human PFC [35]. The results show 
that, independently of the subcellular fraction and with a very similar distribution, the 
three major phospholipid classes are ChoGpl, EtnGpl, and glycerophosphoserines 
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(SerGpl). Overall, ChoGpls comprise around 55% of total phospholipids, and the main 
molecular species are PC(16:0/18:1), PC(16:0/16:0), and PC(18:0/18:1). EtnGpls represent 
about 30% of total phospholipids, with the major molecular species being PE(18:0/22:6), 
PE(18:0/20:4), PE(18:0/22:4), and PE(16:0/22:6). Finally, SerGpls represent 15% of total 
phospholipids, with the major molecular species being PS(18:0/22:6) and PS(18:0/18:1). 
Other minor phospholipids such us phosphatidylinositols (PIGpl) and cardiolipin were not 
analyzed. 
At the membrane level, lipid rafts are microdomains which provide a highly-saturated 
liquid-ordered microenvironment that promotes protein-lipid and protein-protein 
interactions [36, 37]. Lipid rafts comprise a highly dynamic clustering of proteins and 
lipids playing a central role in signal transduction and intercellular communication. Lipid 
rafts from human PFC are characterized by their high level of cholesterol and 
sphingolipids (SM, cerebrosides, and sulfatides), and lower content in GP (particularly 
EtnGpl and SerGpl, both aminophospholipids, and to a lesser degree ChoGpl and PIGpl) 
compared to the non-rafts membranes [38] (see Table 1).  
Fatty acids are prime components of the structural diversity of lipids of neurons and glial 
cells. Indeed, with different permutations of head group and fatty acids, up to 10,000 
theoretical lipid molecular species could be generated [39]. Fatty acids determine the 
functional properties of lipids in PFC which can be ascribed to their roles in the structural 
and functional integrity of membranes, the generation of lipid signaling mediators, and 
the chemical reactivity of the acyl chains [23]. In human PFC, the fatty acid profile is 
characterized by an average chain length of 18 carbon atoms, and a relative distribution 
between saturated (SFA) and unsaturated (UFA) fatty acids of about 40:60 [32]. Among 
SFA, 16:0 and 18:0 are the most abundant. The most abundant UFA are the 
monounsaturated (MUFA) 18:1n-9, and the polyunsaturated fatty acids (PUFAs) 20:4n-6 
(arachidonic acid, AA), and 22:6n-3 (docosahexaenoic acid, DHA) [32, 40, 41] (see Table 
2). The content of these PUFAs in PFC is the highest across human brain regions [32], is 
supported at transcriptional and protein expression levels, and can probably be ascribed 
to inherent neuronal activity [32]. The specific finding that DHA (22:6n-3) is the main 
PUFA present in brain regions is in line with previous findings pointing up the very high 
level of DHA in the whole brain [24]. Interestingly, lipid rafts from human PFC are 
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characterized by their high level of SFA, as well as by reduced amounts of PUFA compared 
to the non-rafts membranes [38].  
The high concentration of PUFAs in neuronal and glial cell membrane GP in PFC not only 
makes them prime targets for lipoperoxidative damage but also enables them to 
participate in long free radical chain reactions. Considering that the peroxidizability index 
(PI) combines the membrane fatty acid composition with the relative susceptibility of 
individual fatty acids to peroxidation [42], the available evidence indicates that PFC shows 
the highest value of PI in the human brain and, consequently, helps explain the greater 
susceptibility of the membrane bilayer to lipid peroxidation [32]. Considering that lipid 
rafts from PFC show enrichment in SFA, it is proposed that this vulnerability particularly 
affects non-raft territories of the cell membrane. However, a greater PI is not necessarily 
associated with a higher degree of molecular damage. In fact, quite the reverse is the 
case. Thus, the higher PI of the human PFC compared to other human brain regions is 
associated with a lower steady-state level of lipoxidation-derived protein damage [32, 
43]. This dissociation is probably due to the lower mitochondrial stress present in PFC 
(based on the levels of the mitochondrial stress marker succinyl-cysteine (SC)) and the 
relevant presence of neuronal adaptive response mediated by the antioxidant response-
signaling pathway Nrf2 (Nuclear factor erythroid 2-related factor), as well as by the stress 
resistance adaptive response mediated by the transcriptional factor REST (RE1-silencing 
transcription factor, also known as neuron-restrictive silencer factor (NRSF))  [32, 44]. 
Globally, human PFC has a specific lipidome that significantly differs from those of other 
human brain regions, tissues, and animal species. Inside the PFC, this lipidome varies in 
the cell layers of the grey matter, the subcellular level (mitochondria and microsomes), 
and even the membrane levels (non-raft vs lipid raft domains). Furthermore, PFC presents 
a specific fatty acid profile characterized by the presence of a high content in PUFAs, 
conferring to PFC a high vulnerability to oxidative conditions, which in turn probably 
demands the presence of adaptive responses to ensure neuronal survival during adult 
lifespan. 
3. The meaning of lipid oxidation and lipoxidation-derived protein adducts 
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Polyunsaturated fatty acids (PUFAs) are abundant constituents preferentially located at 
the sn-2 position in glycerophospholipids (to pointing up plasmalogen-PE) within cellular 
membranes. The fact that lipids constitute a major portion of the plasma, and 
mitochondrial and endoplasmic membranes, establishes the presence of substantial 
concentrations of PUFAs within membranous structures. It is known that PUFA residues 
of lipids (and particularly GP) are very sensitive to oxidation, and this sensitivity increases 
as a function of the number of double bonds per fatty acid molecule [45, 46]. In this 
context, PFC is the human brain region with the highest content in PUFAs which also 
determines that it has the highest content in double bond and peroxidation indexes [32] 
(see Table 2). 
PUFAs are vulnerable to diverse oxidation reactions and radical reactions, both of which 
result in the formation of so-called electrophilic lipid products. Certain oxidation reactions 
involving PUFAs are enzymatically mediated by families of enzymes including the 
lipoxygenases (LOX), cyclooxygenases (COX), and cytochrome P450 [47]. In contrast to the 
highly regulated PUFA oxidation mediated by enzymes, the electrophilic lipid products 
generated by free radical-mediated lipid oxidation are part of the lipid peroxidation 
process (for a review see [48, 49]). Lipid peroxidation occurs in three major phases, 
comprised of an initiation event, chain propagation, and termination (for more details, 
see [50, 51]). Of note, a single initiation reaction is postulated to result in 200 to 400 
propagation cycles, rapidly amplifying free radical damage in highly oxidizing PUFA-rich 
environments. The resulting electrophilic lipid products are reactive aldehydes 
characterized by the common group R-CHO consisting of a carbonyl center bonded to 
hydrogen and an R group arising predominantly as a consequence of oxidative damage 
within the cellular microenvironment. These reactive carbonyl species (RCS) have 
signaling properties, but can also be cytotoxic [23, 42]. It is estimated that over a hundred 
different reactive species can be generated, each with a wide range of reactivity, size, and 
specificity. The most reactive RCS are α,β-unsaturated aldehydes [4-hydroxy-2-nonenal 
(HNE) and acrolein], di-aldehydes [malondialdehyde (MDA) and glyoxal], and keto-
aldehydes [4-oxo-2-nonenal (ONE) and isoketals] [50, 51]. Special mention must be made 
of neuroketals (NKT) which are keto-aldehydes formed by the non-enzymatic oxidation of 
the 22:6n-3 through the neuroprostane pathway [52]. 2-Hydroxyheptanal, 4-
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hydroxyhexenal, cyclopentenone prostaglandins, levuglandins, and oxidized 
phospholipids are other significant aldehydic products of lipid peroxidation of PUFAs.  
As mentioned above, lipid rich membranes provide an optimal environment for producing 
a large abundance of these cytotoxic compounds. For instance, microsomal and 
mitochondrial intra-membrane concentrations of these lipid peroxidation-derived 
electrophilic compounds have been estimated to accumulate to as many as 1-10 mM in 
vivo [50]. The regulatory function and/or cytotoxicity of these aldehydes depend on 
abundance, reactivity, and half-life. Half-life varies significantly, with compounds such as 
ONE and HNE exhibiting half-lives of about 1 second and 2 minutes, respectively. So 
compared with reactive oxygen species (ROS), RCSs have a much longer half-life. This 
property along with the non-charged structure of aldehydes allows them to transiently 
modify distant proteins, lipid membranes (particularly aminophospholipids), and nucleic 
acids [42]. These properties may contribute to a localized bias for molecular adduction by 
RCSs, particularly those with short half-life, as cellular components located within the 
vicinity of lipid peroxidation targets remain more susceptible to generated RCS. By 
contrast, long-lived RCSs can be more destructive because they may have a more 
pronounced global impact by altering a broader array of molecular targets due to their 
transient nature [42, 49]. 
RCS react with nucleophilic groups in macromolecules (lipoxidation reactions) such as 
proteins, nucleic acids, and aminophospholipids, resulting in their chemical and non-
enzymatic modification (see Figure 2). The result is the formation of a diversity of adducts 
and intra- and inter-molecular cross-links collectively called Advanced Lipoxidation 
Endproducts (ALEs) [53]. Thus, by reacting with nucleophilic sites in proteins (basically to 
cysteine (Cys), lysine (Lys), arginine (Arg), and histidine (His) residues), RCSs generate ALE 
adducts such as MDA-Lys, HNE-Lys, NKT-lys, FDP-Lys, carboxymethyl-lysine (CML), and S-
carboxymethyl-cysteine, as well as the cross-links glyoxal-lys dimer (GOLD) and lys-MDA-
lys, among others [53-55]. Several of these compounds have been detected, 
characterized, and located (by mass spectrometry, redox proteomics, and 
immunohistochemistry) in the human PFC. RCSs can also react with the exocyclic amino 
groups of nucleosides to form alkylated products. Guanine is the most vulnerable and 
commonly modified DNA base because of its high nucleophilicity, while MDA-
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deoxyguanosine (M1dG) is the most common adduct [56]. Finally, the amino group of 
aminophospholipids can also react with RCS, leading to the formation of adducts such as 
MDA-PtdEtn and carboxymethyl-PE [57]. To the best of our knowledge, no data are 
currently available about lipoxidation-derived damage to DNA and aminophospholipids in 
human brain. 
The molecular consequences of ALE formation in proteins mostly include deleterious 
structural and functional changes [42]. Thus, ALE formation induces alterations in 
physico-chemical properties (e.g., conformation, charge, hydrophobicity, and solubility), 
formation of intra- and inter-molecular protein crosslinks and aggregates, and loss of 
enzymatic activity, among others; yet it also includes protein activation when the ALE 
formation is in proteins particularly designed to sense and respond to cellular RCS 
production. In other words, protein activation seems to be associated with specific 
protein targets designed to detect RCS which will act as signaling products (see next 
paragraph). In a deleterious way, ALE formation on nucleic acids induces DNA damage 
and mutagenesis, and alterations in physico-chemical and biological properties of the lipid 
bilayer [56, 57]. In this context, a relevant recent study demonstrated that MDA causes 
neuronal mitochondrial dysfunction by directly promoting ROS generation and modifying 
mitochondrial proteins [58]. 
In contrast to their cytotoxic effects, RCSs can also work by sending regulatory signals 
activating specific protein targets which act as adaptive responses designed to decrease 
lipoxidative damage and improve antioxidant defenses. Among these mechanisms 
involved in the modulation of oxidative damage by RCS are i) the modification and 
activation of uncoupling proteins (UCPs) by the RCS hydroxynonenal and the subsequent 
decrease in mitochondrial ROS production [59], and ii) the activation of the antioxidant 
response signaling pathway Nrf2 that includes, among others,  the expression of enzymes 
such as glutathione-S-transferase (GST), specifically designed to detoxify reactive carbonyl 
compounds, and GPx4 (phospholipid hydroperoxide glutathione peroxidase), designed to 
restore reduced states of membrane fatty acids from phospholipids to ensure membrane 
lipid homeostasis [60-62]. The existence of both mechanisms at the brain level and the 
relevant content of Nrf2 in PFC suggest a particular adaptive response in the face of the 
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presence of a lipid microenvironment showing the higher unsaturation degree of human 
brain [32]. 
4. Redox lipidomics and adductomics in human prefrontal cortex aging 
Aging induces changes at all levels of the biological organization which are offset by 
allostatic adaptive response mechanisms geared to preserving the composition and 
function within homeostatic limits. The cell membrane is not an exception [63], and, 
consequently, the longer the optimal membrane lipid composition is maintained, the 
better the cell survival and function. These adaptive mechanisms seem to be particularly 
effective in human PFC since cognitive functions are relatively well-preserved during 
normal aging. Among these mechanisms, the preservation of the lipid membrane 
composition seems to be a key component. 
The first evidence that the membrane lipid composition of the human PFC changes with 
aging emerged in 1990s. The work of Svennerholm and coworkers [64], analyzing the 
membrane lipid composition of human PFC in 118 subjects from 20 to 100 years old, 
found that phospholipids and cholesterol decreased slightly from 20 years of age, 
whereas gangliosides differed from the other lipids, showing an almost constant 
concentration between 20 and 70 years of age. Later, a study focused on the 
mitochondrial and microsomal lipidome of PFC of subjects from 20 to 100 years old [35] 
showed that minor lipid molecular species of ChoGpl, EtnGpl, and SerGpl and containing 
adrenic acid (22:4n-6) and AA specifically decreased along adult life in the PFC, whereas 
particular ChoGpl, EtnGpl, and SerGpl containing DHA increased or remained the same 
during the same period. Finally, in the most recent work [65], the comprehensive 
assessment of lipid concentration changes in the gray matter of the human PFC over the 
adult lifespan (from 30 to 99 years of age) demonstrated that aging affects 14% of 
lipidome (682 from 5024 lipid species showed significant concentration differences) with 
changes starting predominantly at 50-55 years of age, and with differences existing 
between females and males. The lipid functional pathways analyses revealed that the 
biosynthesis of UFA, the glycerolipid metabolism, and the cannabinoid signaling pathways 
were the most affected by aging. 
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Lipidomic changes with aging have also been described in lipid raft from human PFC. 
Thus, Diaz and coworkers [38], using lipid rafts isolated from PFC of healthy subjects aged 
24 to 85, demonstrated that that human cortical lipid rafts are modified by aging in a 
gender-dependent way. The main changes were in levels of plasmalogens, PUFAs 
(especially AA and DHA), total polar lipids (mainly InoGpl, SM, sulfatides, and 
cerebrosides), and total neutral lipids (particularly cholesterol and sterol esters). These 
findings may provide molecular support for the modifications in protein-protein dynamics 
and protein clustering in lipid raft underlying alterations in synaptic plasticity, memory 
retention, and learning during aging [38].  Further studies are, however, needed to 
consolidate these new ideas. 
An additional research line is to be found in studies focused on analysis of the fatty acid 
compositional profile of human PFC [35, 66, 67] in healthy subjects ranging from 20 to 80 
years old. The findings of these studies point to: i) a general sustained and preserved fatty 
acid profile throughout the adult lifespan in PFC; ii) the maintenance or minor changes 
with age in the SFA and MUFA content; iii) the decrease in the PUFA content from series 
n-6 with age, particularly affecting 20:4n-6 and 22:4n-6; and iv) the maintenance or minor 
increase in 22:6n-3 content during aging, with eventual reduction at a very advanced age. 
Sustained SFA, MUFA, and DHA content with age could be interpreted as an adaptive 
response to aging to preserve neurons and cerebral function by helping to maintain the 
geometric properties of lipids and, consequently, functional properties such as exocytosis 
and membrane domain formation [25]. The decreases in PUFAn-6, and particularly the 
20:4n-6 and 22:4n-6 fatty acid content, could have biological effects in that they are 
substrates for lipid mediators. Thus, one explanation for this finding lies in the reported 
decline of the PUFA biosynthesis pathway [67]; however, there is also increased 
consumption by enzymes involved in anti-inflammatory pathways which synthetize a 
diversity of compounds with neuroprotective properties to ensure cell survival and 
functioning during normal aging [67]. For this reason, it is proposed that during normal 
human brain aging, the lipid profile is particularly resistant to changes with age as a result 
of strict control designed to ensure neuronal survival and function. 
Although the membrane lipid composition is largely maintained to guarantee cell survival 
and function, there is a continuous physiological lipoperoxidative attack on the 
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membrane, and the membrane becomes a source of carbonyl compounds with the ability 
to damage other cellular components. In this line, a recent initial study analyzing selected 
specific protein damage markers with mass spectrometry in PFC from healthy humans 
ranging in age from 43 to 86 years old was published [68]. The results demonstrated that 
there is an increase in the steady-state level of oxidative and lipoxidative protein damage 
in human PFC over the adult lifespan, with a breakpoint at 60 years of age (the detected 
and quantified markers for protein oxidation were glutamic semialdehyde and 
aminoadipic semialdehyde, and for protein lipoxidation carboxymethyl-lysine (CML) and 
carboxyethyl-lysine (CEL)). In two additional recent studies, changes with age in the 
protein damage markers derived from the RCS neuroketals (NKT) and malondialdehyde 
(MDA) in human PFC in two groups of individuals, middle-aged and old-aged, were 
analyzed. Steady-state levels of these markers were also analyzed as continuous variables 
in function of age. The levels of NKT- and MDA-protein adducts were significantly 
increased in old-aged human PFC when comparing the two groups, and they remained 
significantly increased considering age as a continuous variable [43, 69]. 
Consequently, it is suggested that progressive lipoxidation-derived molecular damage is a 
conserved, central mechanism of age-related functional decline in human PFC. Indeed, 
several alterations occur in the human PFC with age including increased levels of 
cytokines and of mediators of the innate inflammatory response [70], increased cytotoxic 
oligomeric species [69], regression of dendritic arbors and dendritic spines [71], 
neurotransmitter deficits [72], and reduction in the volume of the gray and white matter 
[73].  
5. Lipoxidation-derived protein damage targets in human prefrontal cortex  
Although the steady-state levels of ALEs in proteins increase in human PFC during aging, 
such evidence does not elucidate the specific mechanisms that cause losses in particular 
cellular/tissue functions. Is there a selective pattern of lipoxidative protein damage? If 
there is, what proteins are the targets? Recent proteomic studies performed in human 
PFC demonstrate that there is only a subset of lipoxidatively-modified proteins, that the 
degree of lipoxidative damage increases with age, and that in all the identified proteins 
increased lipoxidation is not due to a higher content of the corresponding protein but 
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rather to increased flux of protein damage [69, 74]. Importantly, this small but significant 
pool of lipoxidized protein will probably increase over time because the ALEs detected are 
limited to those derived from MDA and NKTs. Consequently, further studies are needed 
to develop a more detailed view. 
The identification of specific lipoxidation-modified proteins in the PFC of adult and aged 
subjects provides an overview of the selective cellular functions that are affected during 
the aging process. The proteins listed in Table 3 represent the biological processes 
affected by RCS-related protein damage. If we consider these molecular pathways, we 
can verify that energy metabolism (with 34.2% of modified proteins, n=12), cytoskeleton 
(22.8% of modified proteins, n=8), and neurotransmission (including neuronal 
communication, synaptic plasticity, and other processes) (with 20% of modified proteins, 
n=7) are the main affected cellular functions. Other significant molecular pathways 
involved, but with a lesser number of modified proteins, are proteostasis (11.4%, n=4 
modified proteins), O2/CO2/heme metabolism (8.5%, n=3), and signal transduction (2.8%, 
n=1) (see Figure 2). 
There is extensive evidence that energy metabolism is particularly affected during PFC 
aging [14, 19, 75]. The reported observations give some clues about the molecular 
substrates of energy failure with PFC aging after the identification of key proteins as 
targets of lipoxidative damage including proteins of glycolysis such as enolases (ENO1, 
ENO2), GAPDH, PGAM1, and PKM; proteins of the tricarboxylic acid (TCA) cycle ACO2, and 
GLUD1; protein subunits of the mitochondrial electron transport chain complexes DLD 
and UQCRC1; and different protein subunits of mitochondrial ATP synthase or complex V 
(ATP5F1A, and ATP5F1B) responsible for oxidative phosphorylation. All of these proteins 
are components of coupled processes which are necessary to fulfill the ATP requirements 
of neurons and glial cells. Neuronal activity is highly dependent on these processes since, 
under normal conditions, glucose is the exclusive energy substrate for the brain [76]. In 
addition, CKB, being a key player in the ‘phosphocreatine circuit’ for cellular energy 
homeostasis, is in charge of rapid ATP production from phosphocreatine reservoirs in 
response to acute increased energy demands in neurons [77]. Thus, CKB provides neurons 
with a reservoir and also an alternative source of ATP to glycolysis, TCA cycle, and 
respiration. 
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Cytoskeletal proteins are also lipoxidized in the second major biological process with a 
great number of modified proteins. The protein targets are beta-Actin, glial fibrillary 
acidic protein, neurofilament light polypeptide, neurofilament medium polypeptide, 
tubulin alpha 1B chain, tubulin beta chain, tubulin polymerization-promoting protein 
(TPPP), and vimentin. Proteins belonging to the main components of cytoskeleton seem 
to be affected: microfilaments, intermediate filaments, and microtubules. These findings 
are in line with previous findings showing that neurofilaments are the main targets of RCS 
adduction in mouse nervous system [78, 79]. Consequently, general neuronal and glial 
processes linked to cytoskeleton can become dysfunctional as a consequence of ALE 
formation in their protein components, but additional functions more specifically linked 
to neurons which require cytoskeleton integrity can also be affected secondarily to 
protein lipoxidation [18, 19]. Some of these functions are vesicle trafficking, maintenance 
of the neuronal caliber, axon guidance, synaptogenesis, and synaptic plasticity. 
The third major biological process that is affected during aging based on the number of 
lipoxidized proteins is neurotransmission. The affected proteins are aspartate 
aminotransferase (GOT1), brain acid soluble protein (BASP1), dihydropyrimidinase Like 2 
(DPYSL2), glutamate-ammonia ligase (GLUL), phosphatidylethanolamine-binding protein 
(PEBP1), 14–3–3 protein gamma (YWHAG), and synapsin 1 (SYN1). These proteins are 
involved in several functions such as neurotransmitter metabolism, axon growth and 
guidance, growth cone collapse and cell migration, neuron differentiation, synaptic 
transmission and plasticity, synaptic vesicle trafficking, signaling pathways, and regulation 
transcriptional activity, among others. These damaged proteins together with those 
linked to the high-energy demands make synapses especially vulnerable to oxidative 
stress damage. Interestingly, these biological processes potentially affected by the 
modified proteins are in line with the concept that most of the functional decline 
associated with normal PFC aging is caused by relatively subtle changes such as those in 
the molecular profile of synapses, altered spine morphologies, reductions in spine 
densities, and loss of dendrites [14] [18]. 
Four damaged proteins are involved in proteostasis. These proteins are alpha-crystallin B 
chain (heat shock protein B5) (CRYAB), heat shock protein 60KDa (HSPD1), protein/nucleic 
acid deglycase DJ-1 (PARK7), and ubiquitin carboxyl-terminal hydrolase L1 (UCHL1). 
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Whereas HSPD1 participates in mitochondrial protein import and macromolecular 
assembly, folding of proteins, and apoptotic process, among other potential functions, 
the rest of the proteins (UCHL1, CRYAB, and PARK7) play a relevant role in oxidative stress 
homeostasis. The case of HSPD1 may be particularly important since decreased content 
of mitochondrial ETC complexes during aging has been described, without any 
explanation [68]. So, it is proposed that defects in HSPD1 activity could induce a 
decreased import of nuclear subunits to the mitochondria with the subsequent 
deficiencies in complex formation which, in turn, affect energy production. As for the 
other proteins, UCHL1 participates in processing of ubiquitin precursors and ubiquitinated 
proteins for proteasomal degradation [80], and CRYAB shows chaperone-like activity and 
prevents aggregation of proteins under stress conditions [81]. PARK7 is a protein and 
nucleotide deglycase that catalyzes the degradation of adducts formed between amino 
groups of proteins or nucleotides and RCS acting as a protein repair system [82-85]. 
Furthermore, it plays an important role in cell protection against oxidative stress and cell 
death, acting as an oxidative stress sensor and redox-sensitive chaperone and protease, 
and it is also involved in neuroprotective mechanisms linked to mitochondrial uncoupling 
proteins, L-type channels, and inflammatory responses. So, the modified chaperones are 
implied in maintaining neuronal oxidative stress homeostasis. Assuming that non-
enzymatic modifications are mostly linked to the loss of function, it may be proposed that 
the inactivation of the modified chaperones favors PFC aging by promoting cellular 
oxidative stress. 
Three proteins related to heme metabolism and oxygen and carbon dioxide regulation, 
biliverdin reductase B (BLVRB), carbonic anhydrase (CA), and hemoglobin A1 (HbA1), are 
also lipoxidatively damaged. CA participates in the conversion of carbon dioxide into 
bicarbonate and participates in the transport of carbon dioxide out of the tissues. BLVDR 
regulates the final step in heme metabolism, but it also regulates glucose metabolism and 
has neuroprotective effects [86]. HbA1 is a component of hemoglobin, the role of which 
in the nervous system is still poorly understood. Hemoglobin has been found in neurons 
where it probably plays a role in oxygen transport or in the regulation of cytosolic 
neuronal oxygen [87]. Lipoxidative damage to these three proteins tags cell oxygen and 
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carbon dioxide regulation as a target of putative cellular respiratory dysfunction in the 
aged PFC. 
Structural characterization of the modified proteins in the healthy adult human PFC with 
PredictProtein software analysis (https://www.predictprotein.org/) reveals some shared 
specific traits which may explain this specificity, rendering proteins more susceptible to 
oxidative damage [69]. Thus, i) the predominant structures of lipoxidized proteins are 
alpha helix and loops, ii) most proteins (excepting cytoskeletal proteins) are globular and 
form soluble coiled-shaped molecules with hydrophobic groups at the core and exposed 
hydrophilic groups to the medium, and iii) among the most recurrent amino acids 
encountered in the exposed regions is lysine, in addition to glutamic acid and aspartic 
acid, a frequent target of lipoxidation on proteins.  Another factor that may be important 
in the selectivity of targeted proteins is the cellular location. Localization of proteins may 
make them more vulnerable as a result of their environmental conditions. Thus, several 
lipoxidized proteins are located in the mitochondria, the principal source of damaging 
free radicals; other proteins are located in membranes belonging to different subcellular 
compartments or even plasma membrane, which show a high content in PUFAs. In 
contrast, yet other damaged proteins, located in the cytoskeleton and the growth cones, 
are involved in neurotransmission, or present in synaptic vesicles. It is worth stressing 
that axons and synaptic terminals have high bioenergetic demands met by continuous 
mitochondrial activity and recruitment, and rapid energy transduction. In addition, axons 
are radial structures with a small diameter in comparison to the cell body, which 
heightens the probability of stochastic interactions between free radicals and membrane 
lipids, thus propitiating lipid peroxidation and further non-enzymatic modification of 
proteins. 
Overall, these findings show that i) the PFC in healthy adults contains lipoxidized proteins, 
ii) the ALE-modified proteins increase in aged subjects, and iii) the selectivity of molecular 
damage is associated with specific structural traits and spatial location. 
6. Advanced lipoxidation end-products (ALEs) and soluble oligomers 
Aberrant protein structures are able to generate soluble oligomers with a high cytotoxic 
potential [88]. For instance, NKT-modified proteins generate aberrant structures with 
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cross-linking and aggregation [52]. For this reason, global levels of NKT-protein adducts 
and the presence of oligomers were analyzed in a recent work [69]. A positive significant 
relation between NKT-modified proteins and soluble oligomer levels in human PFC was 
found, suggesting that modifications of proteins parallels soluble oligomer formation. 
Furthermore, levels of oligomers and NKT increase with age in the PFC. These findings are 
complementary to previous observations showing increased expression levels of soluble 
oligomers in the PFC when comparing middle-aged individuals lacking sAD (Alzheimer 
disease)-related pathology with older cases with sporadic AD-related pathology stages I-II. 
Thus, increased levels of soluble oligomers are indeed a characteristic feature of the aging 
human brain coincidental with the first stages of AD-related pathology [70]. Importantly, 
increased levels of oligomeric species parallel regulation of brain cytokines and mediators 
of the immune response in old age [70]. Whether these coincidences have a cause-effect 
relationship needs further study using appropriate in vitro and in vivo models. Studies in 
post-mortem brains serve to demonstrate that such changes do really exist in the human 
PFC and that they deserve to be investigated deeper.  
7. Interventions against PFC aging 
The identification of interventions that delay PFC aging and can be easily implemented in 
humans is especially important because, to date, no pharmacological treatments able to 
maintain brain function and/or reduce cognitive decline, the risk of dementia, and 
neurodegenerative pathologies have been discovered. In recent decades there have been 
major advances in our understanding of the biology of aging, along with the development 
of nutritional interventions that delay aging including calorie restriction (CR), intermittent 
fasting (IF), protein restriction (PR), methionine restriction (MetR), and chemicals that 
influence pathways linking nutrition and aging processes [89, 90]. 
Growing evidence supports the view that CR/IF/PR/MetR may be helpful in preventing 
age-related changes in the brain associated with cognitive dysfunction [89, 91-93]. CR 
improves cognitive function, including learning and memory, in old rodents and humans 
[94-97], as well as improving the plasticity and recovery of the brain [98, 99], possibly 
mediated by its effects on cell-mitochondrial metabolism [91], nutrient-sensing pathways 
[89], and specific brain-related mechanisms [100].  
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One of the most relevant mechanisms proposed to explain this protective effect involves 
oxidative stress. In this line, a number of studies have shown that CR, as well as PR and 
MetR, may act at the mitochondrial level, reprogramming and improving mitochondrial 
metabolism and thereby decreasing free radical production [91, 101, 102]. In parallel to 
the improvement in mitochondrial free radical generation, there is a reduction in the 
steady-state levels of oxidative damage to proteins, lipids, and DNA in animals subjected 
to CR, IF, PR, and MetR, in whole brain as well as in brain cortex [32, 103-110]. 
Importantly, the set of brain proteins affected in normal aged rats is protected from 
oxidative damage by CR in association with improvement in cognitive functions [111].  
With regards to lipids, several studies have demonstrated that these interventions (CR, 
PR, and MetR) have an impact on brain lipid profiles, inducing changes toward a lipid 
profile that is more resistant to lipid peroxidation which, in turn, leads to a significantly 
lower lipoxidation-derived protein damage level and, consequently, lower loss of function 
[32, 105, 106, 108, 111]. These interventions can also influence brain lipidome. Thus, it 
has been found that 80% MetR in mice induces marked changes in the brain, spinal cord, 
and liver lipidomes [108]. Interestingly, at least 50% of the lipids changed are common in 
the brain and spinal cord but not in the liver, suggesting a nervous system-specific 
lipidomic profile for MetR. The differentially expressed lipids basically include specific 
phospholipid species, which could reflect adaptive membrane responses, and 
sphingolipids, which could lead to changes in ceramide signaling pathways. In addition, 
specific oxidation products derived from cholesterol, ChoGpl, and EtnGpl are significantly 
decreased in brain, spinal cord, and liver from MetR mice. These results demonstrate the 
importance of adaptive responses of membrane lipids leading to increased stress 
resistance in brain. 
Overall, these data provide a valuable insight into the mechanism of dietary restriction 
(CR, IF, PR, MetR) on oxidative stress reduction and functional improvements in the aged 
brain. 
8. Healthy aging brain as prevention for neurodegenerative diseases 
Various morphological, biochemical, metabolic and circulatory alterations, which are 
translated into functional changes, occur in brain aging. The degree of these functional 
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changes will in turn determine whether or not neurodegenerative diseases take place. 
When damage exceeds certain limits age- associated cognitive deterioration occurs. 
Indeed, it has been shown that the physiopathological processes associated to the 
disease begin more than 20 years before the clinical onset of dementia [112]. This 
provides a window of opportunity for finding interventions which can slow or even 
prevent the progress of the disease. Genetics, along with the lifestyle, nutrition, 
environmental factors, etc. can prevent the appearance of these diseases that occur with 
cognitive impairment [113]. This is of the utmost importance, as in many occasions there 
is no treatment for these diseases once the symptoms have debuted. As stated by our 
group in [114] “Only prevention makes sense”, i.e. maintaining a healthy aging brain is 
the best way to prevent neurodegenerative diseases. In this regard, there have been 
some attempts to intervene early in neurodegenerative diseases. The FINGER study is a 
randomised controlled trial with a multidomain intervention consisting of a 2 years 
intervention including diet, exercise, cognitive training and vascular risk monitoring, 
which demonstrated that this multidomain approach could improve or maintain cognitive 
functioning in at-risk elderly people [115]. Two years later, a 24-month multicentre trial in 
which prodromal Alzheimer’s patients received a specific multinutrient showed that they 
had better results on the cognitive-functional measurements and less brain atrophy as 
assessed by magnetic resonance imaging (MRI) [116].  
The Lancet Commission stated in 2017: that we should “be ambitious about prevention” 
[117]. “Active treatment of hypertension in middle aged (45–65 years) and older people 
(aged older than 65 years) without dementia to reduce dementia incidence. Interventions 
for other risk factors including more childhood education, exercise, maintaining social 
engagement, reducing smoking, and management of hearing loss, depression, diabetes, 
and obesity might have the potential to delay or prevent a third of dementia cases”. 
Therefore, maintaining a healthy brain throughout all life by healthy lifestyle habits seems 
to be one of the best ways to prevent neurodegenerative diseases. 
9. Conclusions 
Overall, the available evidence provides robust information about changes in lipidome 
and increased steady-state levels of protein damaged by lipoxidation reactions with PFC 
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aging. The set of damaged proteins compromise vital cell functions such as energy 
metabolism, cytoskeleton, neurotransmission, proteostasis, and oxygen/carbon 
dioxide/heme homeostasis. The affected biological processes may be considered putative 
collaborative factors contributing to the cognitive decline associated with PFC aging. 
Different nutritional interventions can have an impact on these mechanisms, improving 
brain function and delaying changes associated with PFC aging. Since molecular damage is 
already identified in normal middle-aged individuals and increases physiologically in the 
elderly, it seems reasonable to act upon the identified free radical-producing targets and 
lipid metabolism in the appropriate middle-age window.       
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Figure Legends 
Figure 1. Imaging mass spectrometry (IMS) of a human brain section, built by integrating 
selected lipids. The six layers of the gray matter and the white matter (WM) are labeled. 
GPCho, glycerophosphocholine; SPM, sphingomyelin; GPEtn, 
glycerophosphoethanolamine. Modified from [33]. 
Figure 2. Lipid peroxidation in human prefrontal cortex aging. Increased levels of lipid 
peroxidation induce formation of reactive carbonyl species-protein adducts which triggers 
the impairment of energy metabolism, cytoskeleton, neurotransmission, proteostasis, 
and oxygen/carbon dioxide/heme metabolism. The progressive dysfunction of these 
biological processes probably underlies the cognitive decline of PFC associated with the 
aging process. 
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Table 1. Lipid class comparison of lipid rafts and non-raft membranes from gray matter of 
prefrontal cortex from healthy subjects. 
 
 Nonrafts Lipid rafts 
Sphingomyelin 1.97 ± 0.86 11.43 ± 1.44 
Phoshatidylcholine (PC) 9.86 ± 0.87 5.35 ± 0.49 
Phosphatidylserine (PS) 10.85 ± 1.08 6.82 ± 0.50 
Phosphatidylinositol (PI) 3.67 ± 0.59 2.16 ± 0.17 
Phosphatidylglycerol (PG) 2.71 ± 0.58 0.70 ± 0.10 
Phosphatidylethanolamine (PE) 28.72 ± 1.82 20.97 ± 0.57 
Sulfatides 0.00 ± 0.00 10.56 ± 0.68 
Cerebrosides 0.00 ± 0.00 5.10 ± 0.79 
Cholesterol 27.68 ± 1.98 33.04 ± 1.18 
Free fatty acids 10.68 ± 0.92 2.17 ± 0.28 
Sterol esters 0.00 ± 0.00 1.68 ± 0.60 
Total neutral lipids 42.23 ± 2.66 36.90 ± 1.41 
Total polar lipids 57.77 ± 2.66 63.09 ± 1.41 
Phospholipid/cholesterol 2.15 ± 0.18 1.11 ± 0.06 
 
Results are expressed as mole % and represent mean ± SEM. Data from: [38] 
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Table 2.  Fatty acid profiles of healthy adult human prefrontal cortex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed as mol %.  Nd, not detected, identified, or quantified. 
Data were obtained and modified from [32, 40, 41] 
  
Fatty Acid 
Taha et al., 
2013 
Hamazaki et 
al., 2016 
Naudi et al., 
2017 
PFC area BA10 BA8 BA8 
Age (years) 49.7 years 47.9 years 40-49 years 
14:0 nd 0.4 1.3  
16:0 19.4 21.8 20.01  
16:1n-7 0.5 0.5 1.5  
18:0 23.6 25.1 20.4  
18:1n-9/n-7 23.5 19.6 24.6  
18:2n-6 1.0 0.7 1.2  
18:3n-3 nd nd 0.2  
18:4n-3 nd nd 0.4  
20:0 nd 0.2 0.5  
20:1n-9 nd 0.6 1.7  
20:2n-6 nd 0.1 0.4  
20:3n-6 1.0 0.9 1.1  
20:4n-6 8.9 8.6 6.9  
20:5n-3 0.1 nd 0.4  
22:0 nd 0.1 0.5  
22:1n-9 nd 0.06 nd 
22:4n-6 6.5 5.1 4.8  
22:5n-6 1.5 nd 1.04  
22:5n-3 0.5 0.3 0.7  
22:6n-3 13.5 14.5 10.4  
24:0 nd 0.2 0.9  
24:1n-9 nd 0.9 nd 
24:5n-3 nd nd 0.2  
24:6n-3 nd nd 0.1  
Double bond index 182.1 169.9 160.0  
Peroxidation Index 185.8 176.6 153.3  
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Table 3. Lipoxidized proteins identified by redox proteomics in healthy adult/aged human 
prefrontal cortex. 
ID 
(entry 
human) 
Protein Gene Main location Protein 
modification 
by 
Biological process 
P06733 alpha-Enolase ENO1 Cytosol, cell membrane, 
nucleus 
MDA, NKT Energy metabolism 
(glycolysis) 
P09104 gamma-Enolase ENO2 Cytosol, cell membrane MDA Energy metabolism 
(glycolysis) 
P04406 Glyceraldehyde-3-phosphate 
dehydrogenase 
GAPDH Cytosol, cytoskeleton, 
nucleus 
NKT Energy metabolism 
(glycolysis) 
P18669 Phosphoglycerate mutase 1 PGAM1 Cytosol, EVE, nucleus NKT Energy metabolism 
(glycolysis) 
P14618 Pyruvate kinase PKM Cytosol, nucleus NKT Energy metabolism 
(glycolysis) 
Q99798 Aconitate hydratase ACO2 Mitochondrion NKT Energy metabolism 
(TCA cycle) 
P00367 Glutamate dehydrogenase 1 GLUD1 Mitochondrion MDA Energy metabolism 
(TCA cycle) 
P09622 Dihydrolipoyl dehydrogenase  DLD Mitochondrion, nucleus NKT Energy metabolism 
(ETC) 
P31930 Ubiquinol-cytochrome c reductase 
complex core protein 1 
UQCRC1 Mitochondrion MDA Energy metabolism 
(ETC) 
P25705 ATP synthase subunit alpha ATP5F1A Mitochondrion NKT Energy metabolism 
(OxPhos) 
P06576 ATP synthase subunit beta ATP5F1B Mitochondrion MDA Energy metabolism 
(OxPhos) 
P12277 Creatine kinase B-type  CKB Cytosol MDA, NKT Energy metabolism 
(energy 
transduction) 
P17174 Aspartate aminotransferase GOT1 Cytosol NKT Neurotransmission 
P80723 Brain acid soluble protein 1 BASP1 Cell membrane, growth 
cone 
NKT Neurotransmission 
Q16555 Dihydropyrimidinase-related 
protein 2 
DPYSL2 Cytosol, cytoskeleton, 
membrane 
MDA, NKT Neurotransmission 
P15104 Glutamine synthetase GLUL Cytosol, mitochondrion MDA Neurotransmission 
P30086 Phosphatidylethanolamine-binding 
protein 1 
PEBP1 Cytosol NKT Neurotransmission 
P61981 14-3-3 protein gamma YWHAG Cytosol NKT Neurotransmission 
P17600 Synapsin-1 SYN1 Golgi apparatus, synaptic 
vesicle 
NKT Neurotransmission 
P60709 beta-Actin ACTB Cytosol (cytoskeleton) MDA Cytoskeleton 
P14136 Glial fibrillary acidic protein GFAP Cytosol (cytoskeleton) MDA, NKT Cytoskeleton 
P07196 Neurofilament light polypeptide NEFL Cytosol (cytoskeleton) MDA, NKT Cytoskeleton 
P07197 Neurofilament medium polypeptide NEFM Cytosol (cytoskeleton) NKT Cytoskeleton 
P68363 Tubulin alpha 1B chain TUBA1B Cytosol (cytoskeleton) MDA Cytoskeleton 
P07437 Tubulin beta chain TUBB Cytosol (cytoskeleton) MDA Cytoskeleton 
O94811 Tubulin polymerization-promoting 
protein 
TPPP Cytosol (cytoskeleton), 
nucleus 
NKT Cytoskeleton 
P08670 Vimentin VIM Cytosol (cytoskeleton), 
nucleus 
MDA Cytoskeleton 
P02511 alpha-Crystallin B chain 
(Heat Shock Protein B5) 
CRYAB Cytosol, nucleus NKT Proteostasis 
P10809 Heat shock protein 60KDa HSPD1 Mitochondrion MDA, NKT Proteostasis 
Q99497 Protein/nucleic acid deglycase DJ-
1 
PARK7 Cytosol, nucleus, 
mitochondrion, cell 
membrane 
NKT Proteostasis 
P09936 Ubiquitin carboxyl-terminal 
hydrolase L1 
UCHL1 Cytosol, endoplasmic 
reticulum 
NKT Proteostasis 
P00915 Carbonic anhydrase 1 CA1 Cytosol NKT O2/CO2/heme 
metabolism 
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P69905 Hemoglobin subunit alpha HBA1 Cytosol, EVE NKT O2/CO2/heme 
metabolism 
P30043 NADPH-Flavin reductase  BLVRB Cytosol NKT O2/CO2/heme 
metabolism 
B1AKQ8 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta1 
GNB1 Not described MDA Signal transduction 
 
Gene, main location, and biological process are based on what was reported in the 
UniProt database (http://www.uniprot.org/). Abbreviations: EVE, extracellular vesicular 
exosome; TCA cycle, tricarboxylic acid cycle; ETC, electron transport chain;  OxPhos, 
oxidative phosphorylation; ALEs, advanced lipoxidation end-products; NKT, neuroketals; 
MDA, Malondialdehyde. 
Sources: [69,  74]. 
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Figure 2. 
 
 
 
 
 
 
 
 
